Feature | October 15, 2010

CoreValve Transcatheter Valve Trial Receives FDA Approval

October 15, 2010 – An investigational trial of Medtronic’s CoreValve transcatheter aortic valve has been approved by the U.S. Food and Drug Administration (FDA) today. The investigational device exemption (IDE) pivotal clinical trial will enroll more than 1,200 patients at 40 U.S. clinical sites.

The CoreValve system is designed to provide a minimally invasive, nonsurgical treatment option for patients with symptomatic, severe aortic stenosis who are at high risk, or are ineligible, for open-heart surgery. Worldwide, approximately 300,000 people have been diagnosed with this condition. About one-third of these patients are deemed at too high a risk for open-heart surgery, the only therapy with significant clinical effect that is currently available in the United States. The CoreValve System will soon be under investigational use and is not yet commercially available in the United States.

The studies will evaluate the safety and efficacy of CoreValve in two groups of patients with severe aortic stenosis: those who have been deemed high risk for aortic valve surgery, and those who have been deemed at extreme risk for aortic valve surgery (i.e. inoperable).

“There is a distinct need for a new treatment option for many older patients with a severely diseased aortic heart valve and, as the population ages, this need continues to grow,” said Jeffrey Popma, M.D., Medtronic CoreValve U.S. pivotal trial co-principal investigator based at Beth Israel Deaconess Medical Center in Boston.

The CoreValve System is designed with self-expandable technology to replace a diseased aortic valve percutaneously, usually through the femoral artery, without open-heart surgery or surgical removal of the native valve. Since receiving CE (Conformité Européenne) mark in March 2007, the system has been implanted in more than 12,000 patients worldwide in more than 34 countries outside the United States.

“This study represents a significant opportunity to fundamentally change the way we treat Americans with severe aortic stenosis,” said David H. Adams, M.D., professor and chairman of the department of cardiothoracic surgery at The Mount Sinai Medical Center in New York City and co-principal investigator of the CoreValve trial. “Cardiologists and cardiac surgeons will collaborate more closely than ever before to carefully select and deliver this innovative therapy.”

Symptomatic Severe Aortic Valve Stenosis
Aortic stenosis is a condition of the aortic valve which prevents the valve from opening completely, thereby preventing healthy blood flow from the aorta to the rest of the body. While the heart initially compensates for stenosis by thickening its walls to help push blood through the valve, eventually this extra work weakens the heart and leads to an insufficient supply of oxygen-rich blood and sometimes causes a back-up of blood into the lungs. Untreated, aortic valve stenosis can lead to serious heart problems including heart failure and even death.

Study Details
The studies will evaluate the treatment’s safety and efficacy in two groups of patients with severe aortic stenosis: those who have been diagnosed as high risk for aortic valve surgery, and those who have been deemed at extreme risk for aortic valve surgery (i.e. inoperable).

Patients who are considered at high surgical risk will be randomized one-to-one to either transcatheter aortic valve implantation (TAVI) with CoreValve or to surgical aortic valve replacement (SAVR). The primary endpoint for this trial is freedom from all-cause mortality at 12 months.

Study participants deemed at extreme risk for surgical valve replacement will be randomized two-to-one to receive either TAVI with CoreValve or optimal medical management. This trial has co-primary endpoints: all-cause death or major stroke occurring within a minimum of 12 months of follow-up; and a composite of all-cause death, major stroke, days of hospitalization for aortic valve disease, and number of hospitalizations for aortic valve disease occurring within a minimum of 12 months of follow-up.

For more information: www.clinicaltrials.gov, www.medtronic.com

Related Content

Valtech Cardioband, reimbursement, Germany, mitral regurgitation in heart failure
News | Heart Valve Repair| February 09, 2016
Valtech Cardio Ltd. announced that it has received German Neue Untersuchungs und Behandlungsmethoden (NUB) Status 1...
Mount Sinai Heart, TANSNIP-PESA study, worksite lifestyle intervention, cardiovascular risk
News | Cardiac Diagnostics| February 09, 2016
Mount Sinai Heart is undertaking a three-year study to determine whether a workplace-based lifestyle intervention,...
cardiomyocytes, electrical stimulation, human stem cells, Columbia Engineering

Electrically conditioned human cardiomyocytes. Striated ultrastructure containing troponin ( stained in green) forms around cell nuclei (stained in blue.) Image courtesy of Benjamin Lee, Columbia Engineering

News | Stem Cell Therapies| February 09, 2016
Columbia Engineering researchers have shown, for the first time, that electrical stimulation of human heart muscle...
ACC late breakers
News | ACC| February 09, 2016
February 9, 2016 — The late-breaking clinical trial presentations have been announced for the 2016 American College o
transcatheter repair of a mitral valve paravalvular leak

Transcatheter repair of a surgical mitral replacement paravalvular leak with an Amplatzer Vascular Plug II.

Feature | Heart Valve Repair| February 08, 2016 | Dave Fornell
Off-label use of the St.
News | Cardiac Diagnostics| February 08, 2016
February 8, 2016 — A parent’s incarceration has immediate, devastating effects on a family.
medical imaging, low-dose radiation, cancer, LNT model study
News | Radiation Dose Management| February 04, 2016
The widespread belief that radiation from X rays, CT scans and other medical imaging can cause cancer is based on an...
caffeine consumption, extra heartbeats, UCSF study, UC San Francisco, Journal of the American Heart Association
News | EP Lab| February 04, 2016
Contrary to current clinical belief, regular caffeine consumption does not lead to extra heartbeats, which, while...
sleep apnea, heart failure readmissions, Thomas Jefferson University study
News | Heart Failure| February 04, 2016
Early diagnosis and treatment of sleep apnea may reduce six-month readmissions for patients hospitalized with heart...
News | Heart Failure| February 04, 2016
New research from scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) published in the journal...
Overlay Init